Full-Time

Key Account Manager

Multiple Teams

Posted on 9/2/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Remote in UK

Remote

Home-based position in the South East of the UK.

Category
Sales & Account Management (1)
Requirements
  • Excellent selling skills with previous speciality pharmaceutical sales experience and a proven track record in orphan disease area.
  • Advanced account management skills that demonstrate business acumen and an innovative approach to projects & solutions that bring added value to Jazz Pharmaceuticals and other stakeholders.
  • Adaptability and flexibility to be able to optimise the use of multi-channel technology is crucial.
  • Proven track record of success in securing appointments in-person and using remote technologies to deliver successful outcomes.
  • Proven experience of working in a cross-functional team, and demonstrable project planning skills resulting in a measurable success for all parties.
  • Effective and persuasive communicator with professional presentation skills in settings such as face-to-face, multiple group engagements and virtual meetings.
  • Ability to access funding for new and existing drugs, with a detailed and current understanding of the NHS / HSE structure, funding flows and pathways.
  • Proficient IT skills in all business-related packages such as MS office.
  • Experience in the utilisation of CRM tools.
  • Demonstrable ability to engage with customers using multi-channel approaches and platforms.
Responsibilities
  • Promote (in-person and virtually) the haematology product portfolio to maximise the full sales potential on a defined territory.
  • Achieve sales and related performance targets as defined by the management team.
  • Partner with the cross-functional team to orchestrate a multichannel approach to deliver value to NHS/stakeholders.
  • Engage clinical customers in high quality discussions and peer to peer clinical advocacy.
  • Prepare and execute strong territory business and key account management plans, fully utilising agreed processes and procedures.
  • Use multi-channel customer approaches including in-person and virtual calls and meetings to sell the benefits of the haematology portfolio.
  • Map local Healthcare environment to understand referral pathways and key decision makers.
  • Monitor changes and trends impacting the health care system and gain organisational commitment to act on insights.
  • Take accountability for local formulary access in accounts by removing local prescribing barriers.
  • Behave ethically, responsibly, and professionally in accordance with Jazz Pharmaceuticals values and ABPI code of practice.
  • Profile and regularly update key customers and accounts into currently available CRM system.
  • Accurate and timely reporting of customer and business records through CRM system.
Desired Qualifications
  • Previous knowledge and experience of disease area preferred but not essential.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex achieved $1.1B sales in 2025, growing 9% year-over-year.
  • Recorded $4.3B revenue in 2025, guiding $4.25B-$4.5B for 2026.
  • Renee Gala became CEO August 2025, driving 90% revenue growth.

What critics are saying

  • Epidiolex generics erode 25% of revenue within 12-24 months.
  • Japan Phase 3 Epidiolex failure blocks Asian market entry immediately.
  • Chimerix dordaviprone NDA rejected August 2025, wasting $935M.

What makes Jazz Pharmaceuticals unique

  • Focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Acquired GW Pharmaceuticals in 2021, adding blockbuster Epidiolex for epilepsy.
  • Vyxeos from 2016 Celator acquisition treats acute myeloid leukemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE